2019
Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy
Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, Pusztai L, Gross CP, Russell R. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Research And Treatment 2019, 176: 261-270. PMID: 31020471, DOI: 10.1007/s10549-019-05178-z.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioEquilibrium radionuclide angiographyCardiac risk factorsBreast cancer patientsVentricular function assessmentRisk factorsAbnormal LVEFBaseline LVEFCancer patientsBreast cancerFunction assessmentPotential cardiac risk factorsSelf-reported risk factorsAnthracycline-based therapyLeft ventricular function assessmentCoronary artery diseaseCost-effectiveness ratioArtery diseaseTrastuzumab therapyCardiac screeningPatient populationRadionuclide angiographyCardiotoxicity riskPayer perspectiveRetrospective analysis
2017
Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors
Stratton J, Hu X, Soulos PR, Davidoff AJ, Pusztai L, Gross CP, Mougalian SS. Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors. JCO Oncology Practice 2017, 13: jop.2016.018341. PMID: 28267392, DOI: 10.1200/jop.2016.018341.Peer-Reviewed Original ResearchConceptsBaseline DXA scanAromatase inhibitorsBreast cancerDXA scansPostmenopausal womenAI treatmentBaseline bone mineral density testingDual-energy X-ray absorptiometry scanBone mineral density testingBone mineral density evaluationEarly-stage breast cancerX-ray absorptiometry scansBone density screeningOlder Medicare beneficiariesMultivariable logistic regressionSEER-Medicare databaseRepeat DXA scansAI therapyBisphosphonate usePatient characteristicsRetrospective analysisWhite raceMedicare beneficiariesOsteoporosis diagnosisStage I
2012
Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer
Liu JC, Voisin V, Bader GD, Deng T, Pusztai L, Symmans WF, Esteva FJ, Egan SE, Zacksenhaus E. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα− breast cancer. Proceedings Of The National Academy Of Sciences Of The United States Of America 2012, 109: 5832-5837. PMID: 22460789, PMCID: PMC3326451, DOI: 10.1073/pnas.1201105109.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCalcium-Binding ProteinsCD24 AntigenCell DifferentiationCell DivisionEstrogen Receptor alphaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, NeoplasmHumansIntercellular Signaling Peptides and ProteinsJagged-1 ProteinMembrane ProteinsMiceNeoadjuvant TherapyNeoplastic Stem CellsPrognosisReceptor, ErbB-2Serrate-Jagged ProteinsSignal TransductionTrastuzumabTreatment OutcomeConceptsTumor-initiating cellsMammary tumor-initiating cellsBreast cancerClinical outcomesPrognostic signatureHuman epidermal growth factor receptorAnti-HER2 drugsAnti-HER2 therapyHigh-risk patientsHigh-risk subgroupsEpidermal growth factor receptorGrowth factor receptorBC cohortRisk patientsAggressive diseaseBC patientsRetrospective analysisImmune responsePrognostic powerTumor growthPatientsChemotherapyFactor receptorCancerFraction of cells
2010
The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis.
Alvarez R, Bianchini G, Hsu L, Cristofanilli M, Esteva F, Pusztai L, Buzdar A, Hortobagyi G, Valero V. The effect of different sequencing regimens of taxanes and anthracyclines in the primary systemic treatment (PST) of breast cancer (BC) patients (pts): M. D. Anderson Cancer Center retrospective analysis. Journal Of Clinical Oncology 2010, 28: 548-548. DOI: 10.1200/jco.2010.28.15_suppl.548.Peer-Reviewed Original Research
2009
A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients
Pusztai L, Rouzier R, Pusztai L, Ibrahim N. A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients. Journal Of Clinical Oncology 2009, 27: 1028-1028. DOI: 10.1200/jco.2009.27.15_suppl.1028.Peer-Reviewed Original ResearchSubsequent brain metastasesBrain metastasesBreast cancer patientsTN tumorsSpecific nomogramCancer patientsBreast cancerMetastatic triple-negative breast cancer patientsTriple-negative breast cancer patientsD. Anderson Cancer CenterTN breast cancerMetastatic breast cancerAnderson Cancer CenterBM occurrenceMetastatic diseaseMetastatic nodesMetastatic BCInitial diagnosisMetastatic sitesNegative tumorsCancer CenterPreventive treatmentRetrospective analysisFatal eventsHistological characteristics
2007
HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer
Pusztai L, Andre F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, Gonzalez-Angulo A, Symmans W, Hortobagyi G. HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer. Journal Of Clinical Oncology 2007, 25: 548-548. DOI: 10.1200/jco.2007.25.18_suppl.548.Peer-Reviewed Original ResearchPathologic complete responseHER2 overexpressionPCR rateBreast cancerER- cancersHER2 expressionHER2- diseaseRelapse-free survival rateER-negative statusWeekly paclitaxel regimenMicrotubule associated protein tauHigh nuclear gradePaclitaxel regimenPreoperative paclitaxelFAC chemotherapyPreoperative chemotherapyComplete responseHER2 tumorsHER2 statusDoxorubicin chemotherapyNuclear gradeRetrospective analysisPatientsTaxane sensitivitySurvival rate